Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYN303 (Synthis Therapeutics)
- Development stage
- Preclinical
- Lead developer
- Synthis
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
SYN303: sourced facts only. name: "SYN303 is a myofibroblast targeted ADC." [1] target: "Our first-in-class Synthis-003 payload is a novel kinase inhibitor selective for the TGF-ß receptor, ALK5." [1] developer: "SYN303, an ADC that cell-selectively and safely blocks TGF-b in disease areas to improve the therapeutic window." [2] stage: "currently raising a $25M Series A for first in human clinical trials in myelofibrosis patients." [2] stage: "The efficacy of our two drugs has been demonstrated in the bleomycin lung fibrosis mouse model (SYN303)" [1] modality: "SYN303, a, non-cytotoxic, anti-fibrotic antibody drug conjugate" [2]
02
Targets
TGFBR1
Beyond the preview
Go deeper on SYN303 (Synthis Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYN303 (Synthis Therapeutics).